Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for FBRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 183.79M
March 31, 2026 42.10M
December 31, 2025 60.99M
September 30, 2025 84.10M
June 30, 2025 98.61M
March 31, 2025 38.43M
December 31, 2024 52.48M
September 30, 2024 9.366M
June 30, 2024 16.96M
March 31, 2024 28.68M
December 31, 2023 35.31M
September 30, 2023 40.41M
June 30, 2023 24.88M
March 31, 2023 32.95M
December 31, 2022 38.82M
September 30, 2022 42.84M
June 30, 2022 38.21M
March 31, 2022 40.05M
December 31, 2021 41.55M
September 30, 2021 43.65M
June 30, 2021 49.91M
Date Value
March 31, 2021 54.70M
December 31, 2020 58.98M
September 30, 2020 20.32M
June 30, 2020 24.88M
March 31, 2020 2.082M
December 31, 2019 5.746M
September 30, 2019 19.80M
June 30, 2019 36.49M
March 31, 2019 44.85M
December 31, 2018 58.14M
September 30, 2018 47.67M
June 30, 2018 46.09M
March 31, 2018 59.68M
December 31, 2017 71.08M
September 30, 2017 80.12M
June 30, 2017 88.57M
March 31, 2017 -1.508M
December 31, 2016
September 30, 2016
June 30, 2016
March 31, 2016 31.40M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
argenx SE --
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M

Shareholders Equity (Quarterly) Related Metrics